Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors DOI Open Access
Sona Ciernikova, Aneta Sevcikova,

Mária Novisedláková

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4271 - 4271

Published: Dec. 23, 2024

Immunotherapy with immune checkpoint inhibitors represents a revolutionary approach to the treatment of solid tumors, including malignant melanoma, lung cancer, and gastrointestinal malignancies. Anti-CTLA-4 anti-PD-1/PDL-1 therapies provide prolonged survival for cancer patients, but their efficacy safety are highly variable. This review focuses on crucial role gut microbiome in modulating toxicity blockade. Studies suggest that composition may influence response immunotherapy, specific bacterial strains able promote an anti-tumor response. On other hand, dysbiosis increase risk adverse effects, such as immune-mediated colitis. Interventions aimed at microbiome, use probiotics, prebiotics, fecal microbial transplantation, or dietary modifications, represent promising strategies reduce toxicity. The combination immunotherapy microbiome-based strategy opens up new possibilities personalized treatment. In addition, factors physical activity nutritional supplementation indirectly ecosystem consequently improve outcomes refractory leading enhanced patient responses survival.

Language: Английский

Role of gut microbiome in suppression of cancers DOI Creative Commons
Yao Xu, Zhaoyu Gao, Jiaying Liu

et al.

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: April 20, 2025

The pathogenesis of cancer is closely related to the disruption homeostasis in human body. gut microbiome plays crucial roles maintaining its host throughout lifespan. In recent years, a large number studies have shown that dysbiosis involved entire process initiation, development, and prognosis by influencing immune system metabolism. Some specific intestinal bacteria promote occurrence development cancers under certain conditions. Conversely, some other suppress oncogenesis progression cancers, including inhibiting delaying boosting therapeutic effect on cancers. promoting effects been comprehensively discussed previous review. This article will review latest advances mechanisms suppression, providing new perspective for developing strategies prevention treatment.

Language: Английский

Citations

0
Insights into the Relationship Between the Gut Microbiome and Immune Checkpoint Inhibitors in Solid Tumors DOI Open Access
Sona Ciernikova, Aneta Sevcikova,

Mária Novisedláková

et al.

Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4271 - 4271

Published: Dec. 23, 2024

Immunotherapy with immune checkpoint inhibitors represents a revolutionary approach to the treatment of solid tumors, including malignant melanoma, lung cancer, and gastrointestinal malignancies. Anti-CTLA-4 anti-PD-1/PDL-1 therapies provide prolonged survival for cancer patients, but their efficacy safety are highly variable. This review focuses on crucial role gut microbiome in modulating toxicity blockade. Studies suggest that composition may influence response immunotherapy, specific bacterial strains able promote an anti-tumor response. On other hand, dysbiosis increase risk adverse effects, such as immune-mediated colitis. Interventions aimed at microbiome, use probiotics, prebiotics, fecal microbial transplantation, or dietary modifications, represent promising strategies reduce toxicity. The combination immunotherapy microbiome-based strategy opens up new possibilities personalized treatment. In addition, factors physical activity nutritional supplementation indirectly ecosystem consequently improve outcomes refractory leading enhanced patient responses survival.

Language: Английский

Citations

1